KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A systematic review of neuroprotective therapies for visual acuity preservation in retinitis pigmentosa. PMID 42297463 · BMJ Open Ophthalmol · 2026-Jun-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 Studies. PMID 42297437 · J Rheumatol · 2026-Jun-15 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Financial Toxicity of Shorter Versus Longer Partial Breast Irradiation: A Randomized Clinical Trial. PMID 42297155 · Int J Radiat Oncol Biol Phys · 2026-Jun-15 The study is a randomized Phase 3 oncology trial in humans with original results, but it evaluates radiation dosing schedules (a non-drug intervention) and its primary endpoint is financial toxicity (a patient-reported outcome), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the inclusion criteria for a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2. PMID 42297099 · Ann Allergy Asthma Immunol · 2026-Jun-15 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Trabecular surgeries in the management of glaucoma: A review of literature]. PMID 42296663 · J Fr Ophtalmol · 2026-Jun-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Assessing the Reduction of Recurrent Admissions Using OM-85 for the Treatment of Preschool Wheeze (ARROW): Protocol for a Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial. PMID 42294810 · J Paediatr Child Health · 2026-Jun-15 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension. PMID 42290201 · Amyloid · 2026-Jun-15 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer. PMID 42246062 · Cancer · 2026-Jun-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Association between hyperphosphatemia and overall survival among patients with advanced urothelial cancer treated with erdafitinib in phase 2/3 clinical trials. PMID 42240563 · Cancer · 2026-Jun-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial. PMID 41849224 · Clin Cancer Res · 2026-Jun-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial. PMID 41587113 · Clin Cancer Res · 2026-Jun-15 The study is a Phase IIIb trial with a drug intervention and PFS endpoint, but the report is a secondary biomarker analysis of the trial, not the primary result report of the randomized comparison. The abstract does not provide evidence of randomization or a comparison between randomized arms, which is essential for eligibility as a primary RCT result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial. PMID 41587107 · Clin Cancer Res · 2026-Jun-15 This record is a genomic/biomarker analysis (ctDNA) from a Phase III randomized trial. It is not the original formal report of the trial's efficacy results (primary or key secondary endpoint). Therefore, it does not meet the 'original_result' criterion for inclusion in a Kaplan-Meier digitization cohort focused on trial results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis. PMID 42355792 · J Clin Med · 2026-Jun-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). PMID 42288752 · BMC Cancer · 2026-Jun-13 The record is a correction/erratum for a trial, not a primary result report. The title suggests a relevant trial, but without the abstract or full text, key eligibility criteria (phase, time-to-event endpoint, drug intervention details) cannot be established from the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
First-line Therapy for Metastatic Renal Cell Carcinoma: An Updated Network Meta-analysis using Final Follow-up Data. PMID 42288434 · Eur Urol Focus · 2026-Jun-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study. PMID 42287326 · Ann Hematol · 2026-Jun-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
6-mm versus 10-mm covered self-expandable metal stents and plastic stents for malignant distal biliary obstruction in resectable or borderline resectable pancreatic cancer in Japan (STARDOM, JON-2402P): study protocol for a multicenter randomized controlled trial. PMID 42286634 · Trials · 2026-Jun-13 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. PMID 42250575 · Lancet · 2026-Jun-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. PMID 42242268 · Lancet · 2026-Jun-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bawei Aiguning Granules For Lung Cancer Bone Metastases: A Randomized, Double-blind, Placebo-Controlled Trial Protocol With A Representative Case. PMID 42371923 · J Vis Exp · 2026-Jun-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
[Shengqing Jiangzhuo acupuncture method for sepsis-associated gastrointestinal dysfunction: a randomized controlled trial]. PMID 42343512 · Zhongguo Zhen Jiu · 2026-Jun-12 Study is not oncology-related (sepsis-associated gastrointestinal dysfunction). Intervention is acupuncture (non-drug). Primary efficacy endpoints are gastrointestinal function scores and inflammatory markers, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of postoperative esketamine on depression after pancreatoduodenectomy: a randomized controlled trial. PMID 42286774 · Perioper Med (Lond) · 2026-Jun-12 The trial is randomized and oncology-related, but it is not a definitive-phase (Phase III/IIIb or II/III) trial of a drug for an oncological efficacy endpoint. The primary endpoint (postoperative depression incidence) is not a time-to-event efficacy endpoint (e.g., OS, PFS) as required for the oncology Kaplan-Meier digitization cohort. The one-year survival rate is a secondary outcome, but it is not the primary/key secondary endpoint for efficacy evaluation in this context.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Target trial emulation of survival outcomes for clinically localized prostate cancer treatments. PMID 42286375 · Discov Oncol · 2026-Jun-12 The record describes a target trial emulation study using observational data, not a randomized controlled trial report. It lacks a drug intervention and does not report on a Phase III or definitive trial. While it is oncology, human, and reports time-to-event outcomes with HRs, it does not meet the core eligibility criteria of being an original result report from a randomized trial with a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials. PMID 42286315 · Prostate Cancer Prostatic Dis · 2026-Jun-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized Trial of Two Fractionation Schedules of Myeloablative Busulfan with Fludarabine and Cladribine in Acute Myeloid Leukemia or Myelodysplastic Syndromes. PMID 42285355 · Transplant Cell Ther · 2026-Jun-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Evaluation of the TiaoShenZhiAi Regimen for Patients With Ovarian Cancer Experiencing a Psychoneurological Symptom Cluster: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial. PMID 42284089 · JMIR Res Protoc · 2026-Jun-12 This is a clinical trial protocol for an ovarian cancer study with a randomized design and a drug-containing intervention. However, it is not an original formal-result report; it is a protocol without results. Furthermore, the primary efficacy endpoint is the remission rate of a psychoneurological symptom cluster at 3 months, not a primary/key time-to-event efficacy endpoint (e.g., OS, PFS). The secondary endpoint includes 1-year survival, but this is not sufficient as the primary/key endpoint for inclusion. The phase is not explicitly stated in the provided information, but even if inferred, the other critical criteria (original result report, primary time-to-event endpoint) are not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant mFOLFOXIRI with or without cadonilimab versus mFOLFOX6 in locally advanced colorectal cancer: A randomized phase 2 trial (OPTICAL-2). PMID 42134324 · Med · 2026-Jun-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Quality of life and patient-reported outcomes after non-surgical management of early-stage endometrial cancer and endometrial hyperplasia with atypia: a long-term follow-up of the feMMe phase II randomized clinical trial. PMID 42413196 · Int J Gynecol Cancer · 2026-Jun-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer. PMID 42276876 · Eur Urol Oncol · 2026-Jun-11 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer. PMID 42276804 · BMJ Open · 2026-Jun-11 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial. PMID 42276083 · Lancet Infect Dis · 2026-Jun-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Anti-CD123 monoclonal antibodies as therapeutic agents for acute myeloid leukemia: a systematic review. PMID 42257293 · Expert Rev Hematol · 2026-Jun-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluation of a virtual Ayurvedic whole-systems lifestyle intervention for quality of life in breast cancer survivors: An exploratory randomized controlled trial. PMID 42320450 · Explore (NY) · 2026-Jun-10 The record describes a randomized, exploratory pilot study of a non-drug, whole-systems Ayurvedic lifestyle intervention (ADRP) for quality of life in breast cancer survivors. It is a Phase II (pilot) trial, not Phase III/IIIb or Phase II/III. It lacks a drug intervention and does not report on any time-to-event efficacy endpoints (OS, PFS, DFS, etc.), focusing instead on patient-reported outcomes like quality of life, sleep, and digestive symptoms. Therefore, it does not meet the core eligibility criteria for inclusion in this oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis. PMID 42272192 · Acta Derm Venereol · 2026-Jun-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial. PMID 42268294 · Clin Cancer Res · 2026-Jun-10 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury: The VICTORY Randomized Clinical Trial. PMID 42267875 · JAMA · 2026-Jun-10 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review. PMID 42265474 · Eur J Clin Pharmacol · 2026-Jun-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Faricimab: current evidence for the treatment of retinal vein occlusion. PMID 42265442 · Graefes Arch Clin Exp Ophthalmol · 2026-Jun-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial. PMID 42008768 · J Clin Oncol · 2026-Jun-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. PMID 41576297 · J Clin Oncol · 2026-Jun-10 The trial is oncology, human, randomized, Phase III, has a drug intervention, and reports original primary results. However, it is excluded because the primary endpoint is pCR, which does not meet the time-to-event efficacy endpoint criterion (no OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR reported).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical Trials. PMID 42265988 · Am J Respir Crit Care Med · 2026-Jun-09 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Transarterial Embolization Alone Versus Drug-Eluting Microspheres Chemoembolization for Hepatocellular Carcinoma (RAD-18-TAcE): A Multicenter Randomized Clinical Trial. PMID 42265476 · Cardiovasc Intervent Radiol · 2026-Jun-09 The record describes a randomized trial in oncology (hepatocellular carcinoma) with a primary time-to-event endpoint (TTP) and reports final results. However, the trial phase (e.g., Phase III) is not explicitly stated in the provided abstract or metadata, and the intervention (TAE vs. DEM-TACE) is a procedure-based comparison, not a drug-containing intervention where the drug is the primary component of the experimental arm. Therefore, eligibility criteria for both 'phase3_or_definitive' and 'drug_intervention' are not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Continuation of first-line therapy with radiotherapy for oligoprogression versus early switch to second-line therapy in oligoprogressive hepatocellular carcinoma (CROSS): study protocol of a multicentre, randomised, controlled, open-label, phase III trial. PMID 42264528 · BMJ Open · 2026-Jun-09 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Duration of antibiotic therapy for bacteraemia in immune compromised hosts-a post-hoc subgroup analysis of the Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) randomized clinical trial. PMID 42264033 · Clin Microbiol Infect · 2026-Jun-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
STAGE II NON-SMALL CELL LUNG CANCER: UPFRONT SURGERY OR NEOADJUVANT CHEMOIMMUNOTHERAPY. PMID 42264017 · Ann Thorac Surg · 2026-Jun-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Certolizumab inhibits radiographic progression in patients with early rheumatoid arthritis and high rheumatoid factor levels: A pooled, post-hoc analysis of the phase 3 C-EARLY and C-OPERA trials. PMID 42263998 · Joint Bone Spine · 2026-Jun-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Robotic versus open pancreatoduodenectomy (SPAIN Trial): protocol for a multicenter randomized controlled trial assessing safety, efficacy and cost-effectiveness. PMID 42262715 · Updates Surg · 2026-Jun-09 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Low-fat dietary pattern and dementia mortality: a secondary analysis of the Women's Health Initiative dietary modification randomized clinical trial with long-term follow-up. PMID 42262514 · Menopause · 2026-Jun-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
[Efficacy and safety of combining olorigliflozin with metformin in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy]. PMID 42252239 · Zhonghua Yi Xue Za Zhi · 2026-Jun-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke: The INSTANT Randomized Clinical Trial. PMID 42100960 · JAMA · 2026-Jun-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -